Julie L. Gerberding's Insider Trades & SAST Disclosures
Julie L. Gerberding's most recent trade in HilleVax Inc was a trade of 22,500 Stock Option done . Disclosure was reported to the exchange on June 7, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Julie L. Gerberding.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| HilleVax Inc | Julie L. Gerberding | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 22,500 | 22,500 | - | - | Stock Option | |
| HilleVax Inc | Julie L. Gerberding | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2022 | 25,000 | 25,000 | - | - | Stock Option | |
| Merck & Co Inc | Julie L. Gerberding | EVP, Chief Patient Officer | Grant, award, or other acquisition of securities at price $ 73.51 per share. | 24 Feb 2022 | 9,550 | 48,712 (0%) | 0% | 73.5 | 702,021 | Common Stock |
| Merck & Co Inc | Julie L. Gerberding | EVP, Chief Patient Officer | Sale of securities on an exchange or to another person at price $ 87.91 per share. | 01 Nov 2021 | 96,270 | 39,162 (0%) | 0% | 87.9 | 8,462,682 | Common Stock |
| Merck & Co Inc | Julie L. Gerberding | EVP, Chief Patient Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 35,287 | 74,449 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Julie L. Gerberding | EVP, Chief Patient Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 35,287 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Julie L. Gerberding | EVP, Chief Patient Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 30,175 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Julie L. Gerberding | EVP, Chief Patient Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 30,175 | 104,624 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Julie L. Gerberding | EVP, Chief Patient Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 19,394 | 124,018 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Julie L. Gerberding | EVP, Chief Patient Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 19,394 | 9,698 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Julie L. Gerberding | EVP, Chief Patient Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 11,414 | 22,831 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Julie L. Gerberding | EVP, Chief Patient Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 11,414 | 135,432 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Julie L. Gerberding | EVP Strat Comm, GI Pub Policy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2021 | 39,796 | 39,796 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Julie L. Gerberding | EVP Strat Comm, GI Pub Policy | Grant, award, or other acquisition of securities at price $ 72.62 per share. | 26 Feb 2021 | 12,585 | 39,162 (0%) | 0% | 72.6 | 913,923 | Common Stock |
| Merck & Co Inc | Julie L. Gerberding | EVP Strat Comm, GI Pub Policy | Sale of securities on an exchange or to another person at price $ 80.01 per share. | 17 Jul 2020 | 18,174 | 26,577 (0%) | 0% | 80.0 | 1,454,096 | Common Stock |
| Merck & Co Inc | Julie L. Gerberding | EVP Strat Comm, GI Pub Policy | Sale of securities on an exchange or to another person at price $ 80.00 per share. | 17 Jul 2020 | 18,111 | 44,751 (0%) | 0% | 80 | 1,448,880 | Common Stock |
| Merck & Co Inc | Julie L. Gerberding | EVP Strat Comm, GI Pub Policy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2020 | 18,111 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Julie L. Gerberding | EVP Strat Comm, GI Pub Policy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2020 | 18,111 | 62,862 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Julie L. Gerberding | EVP Strat Comm, GI Pub Policy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2020 | 33,226 | 33,226 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges